Salvage Chemotherapy with Weekly Paclitaxel for Metastatic Melanoma

DOI QR Code

Ozaslan, Ersin (Department of Medical Oncology, Erciyes University Faculty of Medicine) ;
Aksoy, Asude (Department of Medical Oncology, Inonu University Faculty of Medicine) ;
Gumusay, Ozge (Department of Medical Oncology, Gazi University Faculty of Medicine) ;
Arpaci, Erkan (Department of Medical Oncology, Sakarya University Faculty of Medicine) ;
Berk, Veli (Department of Medical Oncology, Erciyes University Faculty of Medicine)

Grimaldi AM, Cassidy PB, Leachmann S, Ascierto PA (2014). Novel approaches in melanoma prevention and therapy. Cancer Treat Res, 159, 443-55. https://doi.org/10.1007/978-3-642-38007-5_25
Mamalis A, Garcha M, Jagdeo J (2014). Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res, 306, 511-9. https://doi.org/10.1007/s00403-014-1457-7
Patel PM, Suciu S, Mortier L, et al (2011). EORTC Melanoma Group. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer, 47, 1476-83. https://doi.org/10.1016/j.ejca.2011.04.030
Walker L, Schalch H, King DM, et al (2005). Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res, 15, 453-9. https://doi.org/10.1097/00008390-200510000-00015
Zimpfer-Rechner C, Hofmann U, Figl R et al (2003). Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the dermatologic co-operative oncology group (DeCOG). Melanoma Res, 13, 531-6. https://doi.org/10.1097/00008390-200310000-00012